论文部分内容阅读
目的 观察单或多基因并积极的综合治疗对颅内恶性肿瘤患者生存期及副作用的影响。方法 在 2 6例恶性颅内肿瘤积极的手术、放疗、化疗的同时 ,进行了单HSV -tk/GCV基因或联合B7,IL -2基因治疗。结果 19例患者发热 ,最高达 3 9℃ ,最长持续 4h ,疑与基因治疗有关 ,经常规治疗好转。随访未发现新生肿瘤患者。结论 以上 3种基因治疗方法单或联合运用即使与传统的手术、放疗、化疗方法结合 ,仍不能明显延长颅内恶性肿瘤患者的生存期。但除发热外未发现与基因治疗相关的新生肿瘤或病毒感染等严重并发症。
Objective To observe the effect of single or multiple genes and aggressive combination treatment on the survival and side effects of patients with intracranial malignant tumors. Methods Single HSV-tk / GCV gene or combined with B7 and IL-2 gene therapy was performed in 26 cases of malignant intracranial tumors undergoing positive operation, radiotherapy and chemotherapy. Results 19 patients with fever, up to 39 ℃, the longest duration of 4h, suspected genetic therapy, the conventional treatment improved. Follow-up did not find new tumor patients. Conclusion The combination of the above 3 kinds of gene therapy alone or in combination can not prolong the survival time of patients with intracranial malignant tumor even if combined with traditional operation, radiotherapy and chemotherapy. However, no serious complications such as neoplasia or viral infection associated with gene therapy were found except for fever.